BLI Banque de Luxembourg Investments Buys Shares of 277,650 Zoetis Inc. (NYSE:ZTS)

BLI Banque de Luxembourg Investments purchased a new position in Zoetis Inc. (NYSE:ZTS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 277,650 shares of the company's stock, valued at approximately $45,033,000. BLI Banque de Luxembourg Investments owned approximately 0.06% of Zoetis as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the business. Mission Wealth Management LP raised its position in shares of Zoetis by 2.0% during the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock worth $479,000 after buying an additional 59 shares in the last quarter. VeraBank N.A. raised its holdings in Zoetis by 4.1% during the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company's stock worth $254,000 after purchasing an additional 62 shares in the last quarter. HUB Investment Partners LLC lifted its position in Zoetis by 4.7% in the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock worth $224,000 after purchasing an additional 62 shares during the period. Procyon Advisors LLC boosted its stake in Zoetis by 1.4% during the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock valued at $768,000 after purchasing an additional 63 shares in the last quarter. Finally, Coppell Advisory Solutions LLC increased its position in shares of Zoetis by 18.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock valued at $68,000 after purchasing an additional 64 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Up 1.1 %

NYSE:ZTS opened at $157.43 on Friday. The business's fifty day moving average price is $158.31 and its 200 day moving average price is $167.22. The firm has a market capitalization of $70.24 billion, a price-to-earnings ratio of 28.78, a PEG ratio of 2.78 and a beta of 0.94. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. On average, sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.27%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is presently 36.56%.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the sale, the executive vice president now directly owns 15,781 shares of the company's stock, valued at $2,682,770. This trade represents a 2.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,862 shares of company stock worth $312,254. Corporate insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on ZTS shares. Morgan Stanley decreased their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Barclays lifted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. Stifel Nicolaus cut their target price on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Piper Sandler lifted their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Finally, StockNews.com upgraded Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $214.40.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.